These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35032682)

  • 21. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
    Ng CG; Wong SK; Loh HS; Yee A
    Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting recurrence of major depressive episodes using the Depression Implicit Association Test: A Canadian biomarker integration network in depression (CAN-BIND) report.
    Rnic K; LeMoult J; Torres IJ; Chakrabarty T; Foster J; Frey BN; Harkness KL; Ho K; Li QS; Milev R; Quilty LC; Rotzinger S; Soares CN; Uher R; Kennedy SH; Lam RW
    Psychiatry Res; 2023 Dec; 330():115606. PubMed ID: 37979318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiological Changes Related to Childhood Trauma in Patients with Major Depressive Disorder: An Event-related Potential Study.
    Heo IS; Kwon YJ; Lee HY; Lee HS; Yoon HJ; Shim SH; Kim JS
    Clin Psychopharmacol Neurosci; 2022 Feb; 20(1):167-179. PubMed ID: 35078959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficient inhibition of return for emotional faces in depression.
    Dai Q; Feng Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):921-32. PubMed ID: 19394388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder.
    Ho NCW; Bethlehem RAI; Seidlitz J; Nogovitsyn N; Metzak P; Ballester PL; Hassel S; Rotzinger S; Poppenk J; Lam RW; Taylor VH; Milev R; ; Bullmore ET; Alexander-Bloch AF; Frey BN; Harkness KL; Addington J; Kennedy SH; Dunlop K
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 Aug; 9(8):786-799. PubMed ID: 38679324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.
    Leuchter AF; Cook IA; Marangell LB; Gilmer WS; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; McCracken JT; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):124-31. PubMed ID: 19712979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State-independent and -dependent behavioral and neuroelectrophysiological characteristics during dynamic decision-making in patients with current and remitted depression.
    Kong X; Zhang P; Xiao F; Fang S; Ji X; Wang X; Lin P; Li H; Yao S; Wang X
    J Affect Disord; 2022 Jul; 309():85-94. PubMed ID: 35472481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward a neuroimaging treatment selection biomarker for major depressive disorder.
    McGrath CL; Kelley ME; Holtzheimer PE; Dunlop BW; Craighead WE; Franco AR; Craddock RC; Mayberg HS
    JAMA Psychiatry; 2013 Aug; 70(8):821-9. PubMed ID: 23760393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with escitalopram improves the attentional bias toward negative facial expressions in patients with major depressive disorders.
    Zhou Z; Cao S; Li H; Li Y
    J Clin Neurosci; 2015 Oct; 22(10):1609-13. PubMed ID: 26149404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression.
    Zhdanov A; Atluri S; Wong W; Vaghei Y; Daskalakis ZJ; Blumberger DM; Frey BN; Giacobbe P; Lam RW; Milev R; Mueller DJ; Turecki G; Parikh SV; Rotzinger S; Soares CN; Brenner CA; Vila-Rodriguez F; McAndrews MP; Kleffner K; Alonso-Prieto E; Arnott SR; Foster JA; Strother SC; Uher R; Kennedy SH; Farzan F
    JAMA Netw Open; 2020 Jan; 3(1):e1918377. PubMed ID: 31899530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
    Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
    J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.
    Yang J; Zhou J; Zhou J; Wang H; Sun Z; Zhu X; He Y; Wong AHC; Liu F; Wang G
    J Psychiatr Res; 2022 Feb; 146():172-178. PubMed ID: 34995992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Executive control deficit in depression: event-related potentials in a Go/Nogo task.
    Kaiser S; Unger J; Kiefer M; Markela J; Mundt C; Weisbrod M
    Psychiatry Res; 2003 Apr; 122(3):169-84. PubMed ID: 12694891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.